Healx is an AI-powered techbio company redesigning drug discovery to develop treatments for rare diseases.
There are 10,000 rare diseases and 90% have no approved treatments. Our mission is to deliver unprecedented impact for the rare disease community by pioneering the next generation of drug discovery.
Healx combines artificial intelligence and digital sciences to build a deep biological understanding of drug-disease relationships, uncovering more effective treatments. The Healx platform redesigns the drug discovery by using AI to discover treatments and mechanistic insights without human bias. This approach reduces time, improves the probability of success and has generated a pipeline of over a dozen rare disease programs.
Healx was founded in 2014 in Cambridge, UK, by Dr Tim Guilliams, a Biochemical Engineer and tech entrepreneur, and Dr David Brown, co-inventor of Viagra and former Global Head of Drug Discovery at Roche. In 2019, Healx raised $56 million in Series B funding.
There are 10,000 rare diseases and 90% have no approved treatments. Our mission is to deliver unprecedented impact for the rare disease community by pioneering the next generation of drug discovery.
Healx combines artificial intelligence and digital sciences to build a deep biological understanding of drug-disease relationships, uncovering more effective treatments. The Healx platform redesigns the drug discovery by using AI to discover treatments and mechanistic insights without human bias. This approach reduces time, improves the probability of success and has generated a pipeline of over a dozen rare disease programs.
Healx was founded in 2014 in Cambridge, UK, by Dr Tim Guilliams, a Biochemical Engineer and tech entrepreneur, and Dr David Brown, co-inventor of Viagra and former Global Head of Drug Discovery at Roche. In 2019, Healx raised $56 million in Series B funding.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
UK
Company HQ Country:
United Kingdom
Year Founded:
2014
Main Therapeutic Focus:
Orphan/Rare Diseases
Lead Product in Development:
HLX-0205 and HLX-0206 combination therapy
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
15
Speaker
